• Matthew Cameron, Karen Tam, Khadija Al Wahaibi, Roshanak Charghi, and François Béïque.
• Department of Anesthesia, Jewish General Hospital, Montreal, Quebec, Canada; Department of Anesthesia, McGill University, Montreal, Quebec, Canada. Electronic address: matthew.cameron@mcgill.ca.
• J. Cardiothorac. Vasc. Anesth. 2020 Mar 1; 34 (3): 586-591.

ObjectivesTo determine whether the administration of ketamine during coronary artery bypass grafting (CABG) surgery leads to a reduction in the quantity of opioids required over the first 48 hours after surgery.DesignRandomized, controlled, double-blind clinical trial.SettingSingle university academic center.ParticipantsPatients undergoing CABG surgery with a normal left ventricular ejection fraction.InterventionsKetamine administered intravenously as a bolus dose of 0.5 mg/kg before skin incision, followed by an infusion of 0.5 mg/kg/h until the end of surgery.Measurements And Main ResultsOne hundred eighty-three patients were screened, and 80 patients were randomized. Baseline characteristics were similar between the 2 groups. The intervention group received 53.6 mg (95% confidence interval [CI] 47.1-60.1 mg) of morphine equivalents in the first 48 hours after surgery, whereas the placebo group received 55.7 mg (95% CI 48.4-63.1 mg) over the same time period (p = 0.66). No significant difference was noted in morphine equivalents over the first 6, 12, or 24 hours postoperatively or in maximum, minimum, or average pain scores on postoperative days 1 or 2.ConclusionsThe administration of ketamine during CABG surgery did not result in reduced opioid consumption or pain scores postoperatively.Copyright © 2019 Elsevier Inc. All rights reserved.

20 keywords...

hide…